We developed a computer model to study the use of patients' specimens to assess compliance of cholesterol measurement performance with the 1992 goals of the Laboratory Standardization Panel of the National Cholesterol Education Program. The model uses Monte Carlo techniques to simulate cholesterol measurements that are subject to both systematic and random error. Split-sample measurements by a clinical laboratory and by a reference laboratory are compared by using linear regression to estimate clinical laboratory bias and imprecision; subsequently, according to specified decision limits, the performance of the clinical laboratory is classified as acceptable or deficient. We have quantified the influence of the bias and imprecision of the clinical laboratory, the imprecision of the reference laboratory, the number of split samples compared, and the decision limits on the accuracy of the classification of clinical laboratory performance. Unless the decision limits are carefully selected and a sufficient number of split samples are used, clinical laboratory performance will be frequently misclassified.
cholesterol measurements. ' By 1992, bias from the true value should not exceed 3%, and precisionshould be sufficient to produce a coefficient of variation(CV) of 3% (2).
The LSP goals for accuracy and precision can be achieved with currentlyavailablemethods. Several instruments commonly used in CLs were recently tested and, when used according to manufacturers' instructions, were found consistently able to meet the 1992 goals of the LSP (3) . Yet in recent surveys evaluating imprecision and bias separately, fewer than half of the CLs met the analyticalgoals (4, 5) .
Reliableanalyticalresultsrequireproper calibration, consistent internal quality control, and periodic assessment of laboratory performance through proficiency testing (PT). Frequently, calibrators, quality-control materials, and PT sera have been altered by lyophilization or by the addition of antimicrobialsor preservatives, causing them to behave differently from actual patients'specimens in some analytical systems-socalledmatrix effects (6) .Matrix effectsare properties acquired during the preparation of calibration or control materials and should not be confused with analytical interferences caused by physiological substances such as bilirubin. Matrix effects may lead to improper instrument calibration or erroneous PT results. Consequently, altered sera are inadequate for standardizing the measurement of patients' specimens (5) .
Some have recommended (7) 
Materials and Methods
Our computer-based Monte Carlo model simulates cholesterolmeasurements subject to both systematic error, or bias, and random error, or imprecision. The computer acts as a mock CL in simulating cholesterol measurements on a number ofspecimens. The computer alsoactsas a mock RL in simulatingreplicate measurements on the same specimens. Linear-regression analysisisused toestimate the CV and biasofthe CL, and the CL performance is classified as acceptable (meeting the ISP goals)or deficient (failing to meet the LSP goals), based on defineddecisioncriteria. The model isused to determine the accuracy of these classifications and to evaluate the influence of CL performance level,RL performance level,the number of specimens analyzed, thenumber ofreplicate analyses performedby theRL, and the decisioncriteria on the accuracy ofthe classifications. The general operation ofthe mode! isshown in Figure 1 . The specific assumptions and details are as follows: 
CL Measurements
Simulated CL measurements contain components of both inaccuracy and imprecision. Inaccuracy is modeled as systematic error proportional to the true cholesterol value. Imprecision is modeled as random error,in a gaussian distribution with mean = 0 and the SD proportional to the true value; thus, the magnitude of the variance is greater when the true cholesterol value is higher. This method of modeling imprecision has recently been validated for serum cholesterol measurements (20) .
When the model is evaluated, the CV and bias of the CL performance are first specified, then the analysisof the patients' specimens is simulated. The mode! allows CV to be any nonnegative integer and bias to be any integer.For each specimen, the simulated CL measurement is the sum of the random error and the true cholesterol value scaled by the CL bias, as shown in with E distributed normally ( 0 1-\ \100
Specimen Selection
The number of specimens to be compared by the CL and RL isspecified. The CL selectsan equal number of specimens with CL values in the desirable, borderline high, and high cholesterolranges, for a total of n specimens, n = 3, 6, 9
The CL value will not necessarilybe in the same range as the true cholesterol value.For example, ifthe CL has a biasof 5% and a CV of 3%, a true value of 4.91 mmolIL (1900 mg/L) in the desirable range would be measured by the CL as 5.17 mmol/L (2000 mgfL) or higher and would be misclassifiedas borderlinehigh >46% of the time.
RL Measurements
Simulated RL measurements also contain inaccuracy and imprecisioncomponents, modeled as bias and CV, the replicate values foreach specimen. The CV and bias for the RL performance and the number of replicates are specified at the time the simulations are performed. In our simulations we have assumed the RL is unbiased, though this assumption isnot required by the model. A setofsimulated measurements isshown in Table 1 .
5.CV and Bias Estimates for the CL
In this example 12 specimens are selected, the CL has a 3% CV and 3% bias,the RL has a 2% CV and no bias, and the RL performs three replicatemeasurements of each specimen. The least-squareslinear regressionof the CL values on the means of the RL replicatevalues produces CL bias estimates of 3.81% and 3.06% at 5.17 and 6.21 mmol/L, respectively, and a CV estimate of 3.66%. Ifthe decisionlimitsare setat 3% forCV and 3% for bias, then the CL estimates exceed the decision The true cholesterol value (1)is shown for comparison. limitsand the CL will be incorrectly classified as deficient relative to the LSP guidelines. If, however, the decisionlimitsare raisedto 4% CV and 4% bias,the CL iscorrectly classified as meeting the performance goals.
Probability Calculations
The probability of a CL being classified as acceptable depends on (a)the CL CV and bias,(b) the RL CV and bias,(c) the number ofreplicates performed by the RL, (d) the number of specimens assayed, and (e) the decision limits for CV and bias. For a given combination of these variables, steps 1-6 are repeated 400 times and the proportion of times that the CL performance is classified as acceptable is calculated.
The number of repetitions isspecified at the time the mode! isrun. We have used 400 repetitions as recommended by Westgard etal. (9)and Ehrineyer and Laessig (15) . By varying the mode! parameters, we can determine the probabilities for a range of CL CV-bias pairs and quantify the influence of the RL performance level, the number of specimens, and the decision limits.
Population Statistics
Ifthejointdistribution ofCV and bias throughout the CL population is known, population-dependent statistics such as sensitivity and specificity can be determined and used to assess the utility of split-sample comparisons in the assessment of CL performance and to compare various combinations of the model's variables. The joint distribution of CV and bias and the probabilities produced in step 7 can be used to calculate the proportion of good CLs (i.e., those meeting the LSP goals) classified as acceptable and the proportion of deficient CLs (i.e., those not meeting the LSP goals)classified as deficient. The sensitivity isthe proportionof good CLs that are classified as acceptable;the specificity is the proportionofdeficient CLs classified as deficient.
We have estimated the distributionof CV and the distribution of bias among laboratoriesin the United States(Figure2).These estimatesare based on surveys of clinical laboratories in Nebraska (22) and Virginia (5). Table 2 compares the reported frequencies of CV and biaswith the frequencies used in our model. CL bias and imprecisionare poorly correlated (22) , so the jointdis- 
Let S be a set of variables: specimen number, RL replicatenumber, RL CV, RL bias,and decisionlimits. Let p(ij) be the probability that the CL with CV i and biasj will be classified as acceptable. Let A be the setof acceptable CV-bias pairs, i.e., the setof (ij) pairs with i 3 andj s3, and let D be the set of deficient CV-bias pairs,or the set of(ij) pairs with i >3 on >3. Then the sensitivity-the proportion of good laboratories correctly classified as acceptable-is calculatedby equation 3. The specificity-the proportion of deficient laboratories correctly classified as deficient-iscalculatedby equation 4.
The simulations were run on a Macintosh SE/30 computer (Apple Computer, Inc., Cupertino, CA). The mode! was programmed in TurboPascal (Borland International, Inc., Scotts Valley, CA). Uniform random numbers were generated by the Random X functionof the Standard Apple Numeric Environment (SANE) library. Standard normal random numbers were generated in pairs from uniform random numbers by using the polar algorithm (23).
Results
The basic function of the model is to compare CL and RL measurements of cholesterol to assess whether the CL is meeting the LSP performance goals for accuracy and precision. The probability that the CL will be classified as acceptable depends on the CL's perfor- passing as a function of CL CV and bias for three 0.27 different decision limits-3%, 3.7%, and 5%-for assays of 12 specimens, RL CV= 1%,RLbias = 0,andtheRL measuring each specimen in duplicate. For the CL to be classified as acceptable, the CV estimate and both bias estimates must be less than or equal to the decision limit. As the decision limit is increased, the acceptance frequency increases for all CV-bias pairs. A higher proportion of good laboratories will be correctly classified as acceptable, yielding a higher sensitivity, but a lower proportion of deficient laboratories will be correctly classified as deficient, yielding a lower specificity. Figure 3 shows the influence of the decision limit on the (2) sensitivity, specificity, and efficiency. Efficiency is the proportion of laboratories, both good and bad, correctly classified. Efficiency reaches a maximum of 0.91 when the cutoff' is 3.7%.
The relationship of sensitivity, specificity, and decision limits is demonstrated graphically by receiveroperating characteristic (ROC) curves (24). On the ROC curves in Figure 4 , the acceptance rate for good CLs (sensitivity) is plotted on the vertical axis and the acceptance rate for deficient CLs (1 -specificity) is plotted on the horizontal axis. The decision limits range from 0 to 10%. At the origin of the curves, the decision limit is 0% and all CLs are classified as unacceptable. Initially, as the decision limit is increased, the proportion of good CLs classified as acceptable increases at a rapid rate, while the proportion of deficient CLs classified as acceptable increases at a slower rate. In the middle of the curve, the rate of increase is more nearly equal for good and deficient CLs. In the last part of the curve, a!! of the good CLs are correctly classified as acceptable. However, increasing the decision limit increases the proportion of deficient CLs classified as acceptable until they are all incorrectly classified as acceptable.
ROC curves are useful in selecting decision limits to achieve a desired sensitivity or specificity and in comparing different testing strategies.
The influence of individual model variables can be seen by superimposing ROC curves on the same graph. When two ROC curves are compared, the curve lying closer to the upper left-hand corner shows a higher sensitivity and specificity, producing better differentiation between good and deficient CLs. The 45#{176} line represents a test system with no capability to discriminate between good and deficient laboratories.
Ideally, RLs would be perfectly accurate and precise; however, RL measurements are not perfect. Our model permits the evaluation of the impact of RL error on the accuracy of the classification of CLs. Figure 4 (left) demonstrates the influence of RL imprecision on sensitivity and specificity. RL bias is assumed to be zero, each specimen is measured only once by the RL, and 12 specimens are used. ROC curves for RL CV of 0%, 1%, and 2% are shown. As RL precision increases (decreasing CV), the sensitivity and specificity also increase, increasing the ability to differentiate between acceptable and deficient CL performance.
The effective precision of the RL values may also be increased through replicate measurements of the patients' specimens. In Figure 4 (middle), ROC curves are shown for RLs that measure each specimen once, twice, or three times. Again, the RL is assumed to be unbiased and 12 specimens are used. The RL CV is 2%. Increasing the number of replicates increases the sensitivity and specificity. An important consequence of this finding is that, by performing more replicate analyses, an RL with a higher CV can achieve the same sensitivity and specificity as an RL with a lower CV.
The effect of changing the number of specimens is shown in Figure 4 (right). With each increment in specimen number, the sensitivity and specificity improve. However, the magnitude of this improvement is not constant: the difference between the curves for three and six specimens is much more dramatic than the difference between the curves for 12 and 15 specimens.
Discussion
The establishment of formal guidelines for analytical bias and imprecision makes cholesterol analysis unique in clinical chemistry. It is imperative that methods used to assess clinical laboratory performance be accurate and reliable. The matrix effects associated with lyophiuized specimens make traditional P'I' approaches difficult to correlate with performance on patients' specimens. We have used our mode! to evaluate the ability of an RL to assess CL performance by using split-sample comparisons of patients'specimens. The complexity of this approach to PT requires a complex assessment tool such as computer simulation.
Computer simulation permits systematic and random errors to be modeled separately.Unlike the case in actual clinical practice, in computer models the magnitude of measurement errors is known and can be controlled at specified values, the true cholesterol concentrations are known, and a very large number of analyses over a broad range of values for variables can be performed. The contributions of individual variables can be quantified,and the overall effectiveness of a strategyto assessCL performance can be estimated. The resultsof simulations with our mode! show that various factors influence the abilityof split-sample comparisons to accurately assess CL compliance with the LSP guidelines. The sensitivity and specificity of the classification of CLs are determined by the number of specimens analyzed, the precision of the RL measurements, and the decision limits.
The number of specimens compared by RLs and CLs has a marked effect on the accuracy of the classification of CLs. If too few specimens are used, a high proportion of both good and deficient CLs will be misclassified, and the predictive value of classification will be low. As the number of specimens is increased, the magnitude of improvement declines. The difference between 12 and 15 specimens is minor, whereas the difference between 12 and six specimens is substantial. At a given value of sensitivity, the proportion of deficient laboratories incorrectly classified as acceptable will be roughly twice as high with six specimens as with 12 specimens.
Improving the RL precision also improves the estimates of CL CV and bias, reflected in the more nearly accurate classification of CLs. RL precision can be increased either directly through improved analytical methods or indirectly through increased numbers of replicates analyzed by the RL. The number of replicates needed to achieve certain values of sensitivityand specificity depends on the CV of the RL.
Decision limits can be selected to balance sensitivity and specificity. If decision limits are too low, an unacceptably large proportion of good CLs will be misclassi. fled as deficient; if the decision limits are too high, a large proportion of deficient CLs will not be identified. ROC curves are a useful too! for selecting the most appropriate decision limit.
Our simulation studies provide insight into the potential of split-sample comparisons as a PT technique. Our data suggest that the optimal configuration for a PT program based on split-sample comparisons and linearregression analysis for estimating accuracy and precision of cholesterol measurements would be approximately (a) 12 specimens, (b) RL CV 1%, (c) RL measuring each sample in duplicate, and (d) decision limit = 3.7%. Recent experience indicates that CVs in the range of 1% are attainable by RLs (25) . The acceptance rates-the proportion of CLs expected to be classifledas acceptable-for this configuration are shown in Table 3b as a functionofCL CV and bias.Overall, 91% ofboth good and deficient CLs willbe correctly classified under these conditions. Increasing the specimen number has little effect, whereas changing the decision limit or decreasing the RL precision decreases the proportion of CLs accurately classified. False-negative errorsmisclassifying good CLs as deficient-can be controlled by adjusting the decision limit, but this will increase the rate of false-positive errors-misclassifying deficient CLs as acceptable.
In summary, if split-sample comparisons are used to assess CL performance without due consideration of the influence of the number of specimens used, the CL imprecision and bias, the RL measurement error, the number of replicate analyses by the RL, and the decision criteria, an unacceptably high number of CLs will be misclassified.
Under optima! conditions, CL performance can be correctly identified as acceptable or deficient more than 90% of the time. Decision criteria can be chosen to balance the false-positive and false-negative errors.
Although our discussion has focused on the format of a split-sample PT program for cholesterol and the influence of the format on the accuracy of the PT classifications, additional fundamental issues deserve some comment. Large-scale PT surveys show large intermethod biases for many analytes, including cholesterol, highdensity lipoprotein, triglycerides, thyroxin, and thyrotropin (26). The intermethod differences are generally considered to be artifactual, owing to the artificial matrix of PT materials; however, some investigators are concerned that the matrix effectsmay be masking problems in calibration or basic methodology. The primary appeal of PT with split samples of patients' specimens is the elimination of matrix effects and their confounding influence in the interpretation of PT results. An added advantage of using clinical specimens is that the measurements used for PT are reflective of day-to-day accuracy and precision rather than the special care that external PT specimens may receive.
A potentially serious problem with split-sample PT is the question of "transportation differences," caused by ana!yte instability. During transport,a specimen may be subjected to wide variationsin temperature,perhaps even freezingand thawing. Without proper packaging, the split-sampleanalyte concentrationreceivedby the RL may be very different from that in the sample retained by the CL. Furthermore, the RL sample will likely be analyzed several days later than the CL sample, during which time delay the RL sample may be degraded by chemical reactions, adsorption, or other physical phenomena. Unless the analyte of interest is sufficiently stable, the transit and storage effects may be more problematic than the matrix effects. Finally, split-sample PT shifts much of the analytical burden from the CLs to the RLs. The feasibility of this approach depends not only on the accuracy of the RL results but also on the ability of RLs to handle large
